GlassScriptPhysician profile
Robert Allen Keeter
NPI 1134751738
$5,216.02
in general payments reported to CMS, 2019-2025
28 companies · $1,331 in 2025
The $1,331 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $46.47 · 2022: $751 · 2023: $1,606 · 2024: $1,481 · 2025: $1,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,418.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $868.32 | 2022-2025 | |
| Novo Nordisk INC | $698.74 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $682.39 | 2022-2025 | Farxiga, Airsupra, Tagrisso |
| Lilly USA, LLC | $563.64 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $485.62 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $266.46 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $256.00 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $224.36 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $219.16 | 2022-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.05 | 2021-2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $137.70 | 2022-2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $107.94 | 2022-2023 | |
| Lundbeck LLC | $70.46 | 2024-2025 | Rexulti |
| Abbott Laboratories | $62.32 | 2023 | Freestyle Libre 2 |
| E.R. Squibb & Sons, L.L.C. | $58.36 | 2021-2025 | Eliquis |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $52.72 | 2022-2023 | Verquvo, Belsomra |
| Dynavax Technologies Corporation | $39.31 | 2024 | Heplisav-B |
| Eisai INC. | $37.89 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $35.55 | 2025 | Voquezna |
| Viatris Specialty LLC | $35.44 | 2025 | Yupelri |
| Astellas Pharma US INC | $30.40 | 2022 | |
| Medtronic, INC. | $24.89 | 2025 | Inceptiv |
| Amarin Pharma, INC. | $21.54 | 2022 | |
| Sanofi-Aventis U.S. LLC | $21.28 | 2022 | |
| Shield Therapeutics INC | $19.71 | 2023 | Accrufer |
| Janssen Pharmaceuticals, INC | $19.47 | 2025 | Spravato |
| Dexcom, INC. | $18.60 | 2024 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $13.70 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Keeter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.